Cargando…

P03: RATIONALE AND DEVELOPMENT OF AN E-HEALTH APPLICATION TO DELIVER PATIENT CENTERED CARE DURING TREATMENT FOR MULTIPLE MYELOMA IN THE NETHERLANDS.

Detalles Bibliográficos
Autores principales:	Geerts, P, Eijsink, J, Moser, A, ter Horst, P, Boersma, C, Postma, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012120/ http://dx.doi.org/10.1097/01.HS9.0000829584.24212.94

Ejemplares similares

Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach
por: Geerts, Paul, et al.
Publicado: (2023)

Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands
por: Eijsink, Job F. H., et al.
Publicado: (2020)

P03 COMBINING SKY92 GENE EXPRESSION PROFILING AND IGH CLONALITY TO EVALUATE GENETIC RISK IN IRISH MULTIPLE MYELOMA PATIENTS
por: McAvera, R, et al.
Publicado: (2023)

PA03.03. Effect of manjishtadi lepa in management of ankle sprain
por: Patil, S Suraj, et al.
Publicado: (2013)

Evaluation of primary care midwifery in the Netherlands: design and rationale of a dynamic cohort study (DELIVER)
por: Manniën, Judith, et al.
Publicado: (2012)

P63 BREAKTHROUGH COVID-19 IN FULL VACCINATED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE OF 54 PATIENTS
por: Sgherza, N., et al.
Publicado: (2023)

P03 Not everything is lupus
por: Pinnell, Jonathan, et al.
Publicado: (2021)

P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE
por: Palumbo, F., et al.
Publicado: (2023)

P03.03. Facebook use and professionalism among CAM students
por: Hinck, G, et al.
Publicado: (2012)

P03.16. Student centered learning to practice patient-centered integrative medicine: the ESPRI2T approach
por: Scheffer, C, et al.
Publicado: (2012)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
por: Spiliopoulou, V., et al.
Publicado: (2023)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

P927: CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123 IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER
por: Liu, J., et al.
Publicado: (2022)

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
por: Isa, Reiko, et al.
Publicado: (2022)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION
por: Pfeiffer, C., et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE
por: Massarotti, L., et al.
Publicado: (2023)

The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands
por: Al Khayat, Mohamed N.M.T., et al.
Publicado: (2020)

P856: A SINGLE-CELL FUNCTIONAL PRECISION MEDICINE LANDSCAPE OF MULTIPLE MYELOMA
por: Kropivsek, K., et al.
Publicado: (2022)

P03-03. Protection against SIV by anti HLA class II specific antibody in the macaque model
por: Robinson, MJ, et al.
Publicado: (2009)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

P977: THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA
por: Alp Kirkizlar, Tugcan, et al.
Publicado: (2023)

P850: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA
por: Rodríguez-García, Alba, et al.
Publicado: (2023)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
por: Ludwig, H., et al.
Publicado: (2023)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

Genome-wide nucleosome mapping in multiple myeloma
por: Small, Eliza C, et al.
Publicado: (2013)

PB.03: Evaluating the role of breast MRI at mid-cycle chemotherapy
por: Santosh, D, et al.
Publicado: (2013)

P952: PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER
por: Dou, Xuelin, et al.
Publicado: (2023)

Cytogenetic and interphase Fluorescence in Situ Hybridization studies in patients with multiple myeloma
por: Perumal, G, et al.
Publicado: (2014)

P852: NEOANTIGENS PREDICTED BY THE GNE NEOANTIGEN PIPELINE IN PATIENTS DIAGNOSED WITH DE NOVO MULTIPLE MYELOMA
por: Jiang, Y., et al.
Publicado: (2022)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

PA01.03. Rural health and snakebite
por: Dutta, Arun Kumar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6f49qustcs3birta53a3hs07fc